MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ:VITA), a spine and orthopedic biosurgery company, reported that it has received CE Mark approval for its VITAGEL® Surgical Hemostat product and CELLPAKER® plasma collection system. The approval allows Orthovita to market VITAGEL as a surgical hemostat in Europe.
